

THU0243

### HSA\_CIRC\_0123190 FUNCTIONS AS A COMPETITIVE ENDOGENOUS RNA TO REGULATE APLNR EXPRESSION BY SPONGING HSA-MIR-483-3P IN LUPUS NEPHRITIS

C. Zhang<sup>1</sup>, C. Gao<sup>1</sup>, X. Di<sup>1</sup>, S. Cui<sup>1</sup>, W. Liang<sup>1</sup>, W. Sun<sup>1</sup>, M. Yao<sup>1</sup>, Q. Wang<sup>1</sup>, Z. Zheng<sup>1</sup>. <sup>1</sup>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

**Background:** Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus (SLE). Circular RNAs (circRNAs) can act as competitive endogenous RNAs (ceRNAs) to regulate gene transcription, which is involved in mechanism of many diseases, such as, autoimmunity diseases. However, the role of circRNA in lupus nephritis has been rarely reported.

**Objectives:** In this study, we aim to investigate the clinical value of circRNAs and explore the mechanism of circRNA involvement in the pathogenesis of LN.

**Methods:** Renal tissues from three untreated LN patients and three normal controls (NCs) were used to identify differently expressed circRNAs by RNA sequencing (RNA-seq). Validated assays were used by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Correlation analysis and receiver operating characteristic (ROC) curve were used to reveal the clinical value of selected circRNA, miRNA and mRNA. The interactions between circRNA and miRNA, or miRNA and mRNA were further determined by luciferase reporter assay. The degrees of renal fibrosis between the two groups were compared by Masson-trichrome staining and immunohistochemistry staining.

**Results:** 159 circRNAs were significantly dysregulated in LN patients compared with NC group. The expression of hsa\_circ\_0123190 was significantly decreased in renal tissues of patients with LN ( $p=0.014$ ), as same as the sequencing results. The area under the ROC curve of hsa\_circ\_0123190 in renal tissues was 0.820. Bio-informatic analysis and luciferase reporter assay illustrated that hsa\_circ\_0123190 can act as a sponge for hsa-miR-483-3p which was also validated to interact with APLNR mRNA. APLNR mRNA expression was positively related with chronicity index (CI) of LN ( $R^2=0.452$ ,  $p=0.033$ ). Finally, the factors of renal fibrosis, especially TGF- $\beta$  ( $p=0.018$ ), were more pronounced in the LN group.

**Conclusion:** Hsa\_circ\_0123190 could function as a ceRNA to regulate APLNR expression involved in renal fibrosis by sponging hsa-miR-483-3p in LN

#### References:

- Aljaberi N, Bennett M, Brunner HI, Devarajan P. Proteomic profiling of urine: implications for lupus nephritis. Expert review of proteomics. 2019;16(4):303-13.
- Zheng ZH, Zhang LJ, Liu WX, Lei YS, Xing GL, Zhang JJ, et al. Predictors of survival in Chinese patients with lupus nephritis. Lupus. 2012;21(10):1049-56.
- Chen LL. The biogenesis and emerging roles of circular RNAs. Nature reviews Molecular cell biology. 2016;17(4):205-11.
- Mahmoudi E, Cairns MJ. Circular RNAs are temporospatially regulated throughout development and ageing in the rat. Scientific reports. 2019;9(1):2564.
- Liang D, Wilusz JE. Short intronic repeat sequences facilitate circular RNA production. Genes & development. 2014;28(20):2233-47.
- Tan WL, Lim BT, Anene-Nzelu CG, Ackers-Johnson M, Dashi A, See K, et al. A landscape of circular RNA expression in the human heart. Cardiovascular research. 2017;113(3):298-309.
- Zhao Z, Li X, Jian D, Hao P, Rao L, Li M. Hsa\_circ\_0054633 in peripheral blood can be used as a diagnostic biomarker of pre-diabetes and type 2 diabetes mellitus. Acta diabetologica. 2017;54(3):237-45.
- Ouyang Q, Huang Q, Jiang Z, Zhao J, Shi GP, Yang M. Using plasma circRNA\_002453 as a novel biomarker in the diagnosis of lupus nephritis. Molecular immunology. 2018;101(undefined):531-8.
- Luan J, Jiao C, Kong W, Fu J, Qu W, Chen Y, et al. CircHLA-C Plays an Important Role in Lupus Nephritis by Sponging miR-150. Molecular therapy Nucleic acids. 2018;10(undefined):245-53.
- Kuschnerus K, Straessler ET, Müller MF, Lüscher TF, Landmesser U, Kränkel N. Increased Expression of miR-483-3p Impairs the Vascular Response to Injury in Type 2 Diabetes. Diabetes. 2019;68(2):349-60.
- Huang Z, Wu L and Chen L. Apelin/APJ system: A novel potential therapy target for kidney disease. Journal of cellular physiology. 2018;233(5): 3892-900.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.4025

THURSDAY, 04 JUNE 2020

### SLE, Sjögren's and APS - clinical aspects (other than treatment)

THU0244

### 3 YEAR FOLLOW UP OF AN AT-RISK CONNECTIVE TISSUE DISEASE COHORT: ANALYSIS OF CLINICAL, GENE EXPRESSION AND FLOW CYTOMETRIC BIOMARKERS

S. U. Hassan<sup>1</sup>, Z. Wigston<sup>1</sup>, A. Psarras<sup>1</sup>, K. Dutton<sup>1</sup>, M. Y. MD Yusuf<sup>1</sup>, E. Vital<sup>1</sup>. <sup>1</sup>University of Leeds, Leeds, United Kingdom

**Background:** We previously reported results from the first 118 "At-Risk" of autoimmune connective tissue disease (AI-CTD) individuals (i.e. ANA positivity, non-specific symptoms of  $\leq 1$  year and treatment naïve). At 1 year, 16% progressed to meet classification criteria for an AI-CTD. This was predicted by high baseline interferon (IFN) Score B and family history of RMD[1].

However, some may have progressed at later time points, or had clinically significant disease despite not meeting diagnostic criteria. Longer term outcomes, baseline and follow up flow cytometry biomarkers were never reported.

#### Objectives:

- Describe detailed analysis of 3-year follow-up data of the At-Risk cohort
- Evaluate flow cytometric biomarkers as predictors of these outcomes
- Analyse follow up biomarkers

**Methods:** We conducted a prospective observational longitudinal study of At-Risk individuals in Leeds (n=150). Patients were assessed at baseline, then annually for 3 years. Depending on diagnostic criteria and need for therapy, patients were grouped as follows:

- Absolute non-progressors (no clinical diagnostic criteria)
- Undifferentiated CTD (U-CTD) ( $\geq 1$  clinical criteria at baseline persisting at follow-up but not meeting criteria). This group was subdivided into those who required treatment with an immunosuppressant (IS) excluding antimalarials and those who did not
- Year 1 progressors (meeting criteria for an RMD by 1 year)
- Late progressors (meeting criteria for AI-CTD beyond 1 year follow-up).

Bloods were analysed at baseline and 1 year for two IFN-stimulated gene expression scores previously described[2], monocytes and subsets of B and T cells using flow cytometry. Association between clinical criteria, biomarkers at baseline and long term outcomes were tested using ANOVA.

**Results:** 3 year follow up data was available in 147/150 patients. Outcomes were: Absolute non-progressors: 63/147 (43%); U-CTD: 54/147 (37%); Year 1 progressors: 21/147 (14%) [SLE=18; pSS=3]; Late progressors (in years 1-2): 9/147 (6%) [SLE=7; pSS=2]. None progressed or required IS initiation beyond the first 2 years of follow-up. In U-CTD group, 7/54 (13%) were prescribed an IS. This work describes a larger group of 36/147 (24%) At-Risk individuals who developed clinically significant disease (CSD: progressors or need for IS) versus clinically non-significant disease (CNSD: absolute non-progressors or UCTD not needing IS). Analysis of baseline biomarkers between CSD and CNSD confirmed a significant difference in IFN Score B (mean difference -0.74,  $p = 0.027$ ), but not IFN Score A (mean difference -0.68,  $p = 0.15$ ). In flow cytometry analysis, there was also a significant difference in percentage monocytes (mean difference -4.09,  $p = 0.004$ ) but no other subset. Absence of clinical criteria at baseline did not predict clinical outcome, and no one clinical criterion had greater predictive value.

In follow up samples we noted a significant reduction in expression of IFN Score B in both groups, regardless of whether they received antimalarials or IS therapy.

**Conclusion:** Here we report findings of a larger group of 24% At-Risk individuals who developed CSD (progressors and patients who did not meet criteria but needed IS therapy). These results provide a more complex picture of IFN activity in the initiation of SLE than previously suspected. First, we confirm that a specific subset of ISGs rather than a classic IFN signature predicts progression. Second, the reduction in IFN-Score-B in both groups suggests that IFN Score B activity is a transient phenomenon, playing a greater role in disease initiation than in disease maintenance.

#### References:

- Md Yusof MY, Psarras A, El-Sherbiny YM, et al. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis. 2018 Oct;77(10):1432-1439.
- El-Sherbiny YM, Psarras A, Md Yusof MY, et al. A novel two score system for interferon status segregates autoimmune diseases and correlates with clinical features. Sci Rep. 2018 Apr 11;8(1):5793.

**Disclosure of Interests:** Sabih-UI Hassan: None declared, Zoe Wigston: None declared, Antonios Psarras: None declared, Katie Dutton: None declared, Md Yuzaiful Md Yusof: None declared, Edward Vital Grant/research support from: AstraZeneca, Roche/Genentech, and Sandoz, Consultant of: AstraZeneca, GSK, Roche/Genentech, and Sandoz, Speakers bureau: Becton Dickinson and GSK

**DOI:** 10.1136/annrheumdis-2020-eular.3661

THU0245

### PENALIZED REGRESSION ANALYSIS IDENTIFIES CRITERIA AND NON-CRITERIA FEATURES THAT MAY INCREASE THE ACCURACY OF EXISTING SETS OF CRITERIA FOR CLASSIFYING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

C. Adamichou<sup>1</sup>, I. Genitsaridi<sup>1</sup>, D. Nikolopoulos<sup>2</sup>, A. Bortoluzzi<sup>3</sup>, A. Fanourakis<sup>2</sup>, E. Kalogiannaki<sup>1</sup>, E. Papastefanakis<sup>1</sup>, I. Gergianaki<sup>1</sup>, P. Sidiropoulos<sup>1</sup>, D. Boumpas<sup>2</sup>, G. Bertias<sup>1</sup>. <sup>1</sup>University of Crete Medical School, Iraklio, Greece; <sup>2</sup>National and Kapodistrian University of Athens, Athens, Greece; <sup>3</sup>University of Ferrara, Ferrara, Italy